Importance of reliable, consistent blood pressure measurement on clinical care and patient outcomes
Thomas Schwieterman, MD, and Randy Wexler, MD, MPH, FAAFP, discuss the key role blood pressure measurement plays in both disease management strategies and metrics for value-based care models — plus, how doctors can improve measurement positioning and protocol.
Presented by: Thomas D. Schwieterman, M.D., MBA & Randy Wexler MD, MPH, FAAFP
Thomas D. Schwieterman, M.D., MBA
Vice President of Clinical Affairs and
Chief Medical Officer
As Vice President of Clinical Affairs and Chief Medical Officer for Midmark Corporation, Dr. Tom Schwieterman has a profound understanding of the trends and issues driving the healthcare industry through significant change and evolution. His experience as a private practice physician for 12 years in a rural community gives him a unique perspective on problems and opportunities facing physician practices, especially at the point of care.
Randy Wexler MD, MPH, FAAFP
Professor of Medicine
Vice Chair for Academics
Ohio State University
Randy is a Professor of Family Medicine and Vice Chair for Academics at the Ohio State University. He received his medical degree from Wright State University, and his MPH from the Ohio State University College of Public Health. His research interests include improved cardiovascular care in the primary care setting and evolution of value-based health care models. Dr. Wexler has received research funding from NIH, AHRQ, and Ohio Medicaid, as well as various Foundations.
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
